Eli Lilly will cut prices on its popular drugs Mounjaro (diabetes) and Zepbound (weight-loss) in Canada by 20% or more, according to a report from The Globe and Mail.
This strategic decision impacts two of the company's key growth drivers within the Canadian market.
The move follows recent pharmaceutical industry price adjustments for weight-loss medications. Specific market reaction to this Canada-specific pricing decision has not yet been widely reported.